Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond

A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.

May 18th 2022

The panel concludes with final thoughts on unmet needs and future perspectives for the treatment of advanced clear-cell RCC.